A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Refractory Cancer
Endometrial Carcinoma (EC)
Squamous Head and Neck Carcinoma
pMMR/MSS Adenocarcinoma of the Colon or Rectum
Cutaneous Melanoma
Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: GV20-0251
BIOLOGICAL: GV20-0251
BIOLOGICAL: GV20-0251 and Pembrolizumab [KEYTRUDA®]
BIOLOGICAL: GV20-0251 and Pembrolizumab [KEYTRUDA®]

Sponsor

GV20 Therapeutics

Collaborators

[object Object]